Batlle et al. (2020) hypothesized that soluble recombinant ACE2 proteins administration could attenuate coronavirus infection by prevent binding of the viral particle to the structural transmembrane domain of full-length ACE2 in a competitive way. In addition, as discussed by Gheblawi et al. (2020), maintaining ACE2 levels in patients with or predisposed to risk factors for CVD such as DM, hypertension, and obesity wards off the advancement of these comorbidities in instances where the patient contracts SARS-CoV-2 by maintaining a level of ACE2/Ang1–7/Mas negative counter-regulation. Here, ACE2 is linked to obesity due to melanocortin 4 receptor deficiency.